Filing Flows › Fulgent Genetics (FLGT) › Q2 2025
Fulgent Genetics (FLGT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 1, 2025
Fulgent Genetics (FLGT) reported revenue of $81.8M for the second quarter 2025 (Q2 2025), +15% from a year earlier and +11% from the quarter before. Operating margin was -24.1%, net loss $19.3M (23.5% of revenue).
Fulgent Genetics, Q2 2025: revenue $81.8M (+15% year over year), operating margin -24.1%, net loss $19.3M, operating cash flow −$30.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $81.8M | +11% | +15% |
| Operating profit | −$19.7M | — | — |
| Net earnings | −$19.3M | — | — |
| Operating cash flow | −$30.2M | — | — |
What changed
Revenue was $81.8M in Q2 2025, up 15% year over year and up 11% from the previous quarter.
Gross margin was 42.1%, up 4.8 points from a year earlier. Operating costs exceeded revenue by $19.7M, an operating margin of -24.1%. Operating expenses grew 19% against revenue growth of 15%. The fastest-growing cost line was Sales & marketing (+43%). The quarter ended with a net loss of $19.3M, wider than the previous quarter's $11.9M loss. Minority interests bore $299K of it: to shareholders the quarter was a loss of $19.0M.
Operating cash flow was −$30.2M. Non-cash charges added back $6.1M of depreciation and amortization and $10.0M of share-based compensation. Working capital and other items used $27.0M. Capital expenditures of $6.8M exceeded it, leaving free cash flow of −$37.0M.
Questions
What was Fulgent Genetics' revenue in the second quarter 2025?
Fulgent Genetics (FLGT) reported revenue of $81.8M for the second quarter 2025 (Q2 2025), +15% from a year earlier and +11% from the quarter before.
Was Fulgent Genetics profitable in the second quarter 2025?
Operating loss was $19.7M (-24.1% of revenue) and net loss $19.3M.
Source: Fulgent Genetics 10-Q on SEC EDGAR.